Recent 8-K filings for IRMD

• May 1, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Iradimed Q1 revenue $22.0M (+13% YoY), EPS $0.45; declares $0.20 dividend; reaffirms FY guidance

  Q1 revenue $22.0M (+13% YoY); GAAP diluted EPS $0.45 (+22% YoY); non-GAAP EPS $0.49 (+17% YoY).

• February 10, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Iradimed reports record Q4 revenue $22.7M, EPS $0.50; raises dividend to $0.20

  Q4 2025 revenue $22.7M (+17% YoY); GAAP diluted EPS $0.50 (+25%), non-GAAP $0.54 (+23%).

• December 8, 2025, 6:59 PM ET dividend materiality 0.65 positive item 8.01item 9.01

  iRadimed declares special cash dividend of $0.50 per share

  Special dividend of $0.50 per share payable Dec 30, 2025 to holders of record Dec 17, 2025.

• November 3, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Iradimed reports record Q3 revenue of $21.2M, up 16% YoY; raises FY2025 guidance

  GAAP diluted EPS $0.43, non-GAAP diluted EPS $0.47; net income $5.6M (+10% YoY).

• August 1, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Iradimed reports record Q2 revenue of $20.4M (+14% YoY), raises FY2025 guidance

  GAAP diluted EPS of $0.45 (up 18% YoY); non-GAAP diluted EPS of $0.49 (up 17% YoY).

• May 29, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  iRadimed receives FDA 510(k) clearance for next-gen MRidium 3870 infusion pump

  FDA granted 510(k) clearance on May 29, 2025 for the MRidium 3870 IV Infusion Pump System.

• May 5, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Iradimed Q1 record revenue $19.5M (+11% YoY); EPS $0.37 GAAP, $0.42 non-GAAP

  Record Q1 revenue of $19.5M, up 11% YoY from $17.6M; GAAP diluted EPS $0.37 (+16% YoY).

• February 13, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  IRADIMED Q4 revenue $19.4M (+11% YoY); raises quarterly dividend to $0.17/share

  Q4 revenue record $19.4M (+11% YoY); GAAP EPS $0.40, non-GAAP EPS $0.44.

• January 10, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  iRadimed Q4 2024 revenue range $19.2-$19.4M, record; full-year revenue $73.1-$73.3M, up 11-12% YoY

  Q4 2024 revenue ~$19.2M-$19.4M, a record; YoY growth 10-11%, sequential growth 5-6%.

• October 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  IRADIMED Q3 revenue $18.3M (+11% YoY), raises FY EPS guidance, declares $0.15 dividend

  Record Q3 revenue of $18.3M, up 11% YoY from $16.5M; GAAP diluted EPS $0.40, Non-GAAP $0.43.

• August 1, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  IRADIMED reports record Q2 revenue $17.9M, GAAP EPS $0.38

  Revenue of $17.9M, up 11.2% YoY; operating income $5.6M, up 13.4%.

• May 2, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  IRADIMED reports record Q1 revenue of $17.6M, up 13.7% YoY; EPS $0.32 GAAP, $0.36 non-GAAP

  Q1 2024 record revenue $17.6M, +13.7% YoY; operating income $4.7M, +18.5%.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event earnings

13 positive 0 negative 4 neutral

source · IRMD on sec.gov